Responsible research

GSK continues to be committed to Research and Development of medicines that will improve the quality of life of people around the world and truly make a difference to patients.

Patient safety is always our priority and hence, a fundamental focus of our research and development activities is the evaluation of benefits and risks of our products. This involves rigorous checks not just before approval, but also continuous monitoring while the product is in use. 

The Company R&D unit in India, namely Pharmaceutical Research & Development (PR&D) is approved by Department of Science and Industrial Research, Government of India.

To address ethical concerns related to biomedical research, we:

  • are open about our approach and participate in discussions on research practices
  • regularly engage with academic scientists, regulators, policy makers and other
    stakeholders involved in this field of work


Business responsibility is about our commitment to be open and transparent about our operational activities. This is of fundamental importance in the healthcare industry where research is conducted to heal life threatening diseases. A key success factor for GSK India has been the flexibility and freedom within the global ethical and commercial framework to adopt India-specific strategies. This gives significant speed in decision-making and responding to the local market dynamics.

We are transparent as far as possible with our clinical trial data, including publishing clinical study reports (without patient-level data) for all outcome trials of medicines conducted by GSK, whether positive or negative. Through an appropriate process, we also make available to researchers access to anonymised patient level data to further scientific enquiry.

Medical governance framework 

Our medical governance framework ensures we always apply recognised principles to the discovery, development and marketing of GSK products. These principles are:

  • good medical science
  • integrity
  • ethics and standards

Overall responsibility for medical governance sits with our Chief Medical Officer (CMO), who is the most senior physician at GSK, supported by the Medical Governance Executive Committee (MGEC). We require external collaborators to adhere to the same medical governance standards as we do.

All medicines carry potential risks as well as benefits. Although our studies are carefully designed to test safety and tolerability, sometimes adverse events, potential safety issues or side effects may only be detected after approval when a product is being used by patients.

How we work with doctors 

We are committed to being a values-based business. This ranges from the way we conduct our research, to our approach to sales and marketing, to the way we interact with patients and doctors. Through consistent ethical practices, commitment to providing world-class medical information and significant investments in training and developing its field force, GSK has partnered with the physician community in India to enhance fundamental progress of medical science and to help meet patient and public health needs.